NCT06753136View on ClinicalTrials.gov

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

February 28, 2030

Conditions
Primary Visceral Tumors of Any HistotypeVisceral LesionsLiver CancerLiver Metastasis Colon CancerMelanomaPrimary Pancreatic TumorRetroperitoneal SarcomaAbdominal and/or Peritoneal LocalizationsMerkel Cell CarcinomaSquamous Cell CarcinomaSecondary Visceral Localizations of Any HistotypeNon-melanoma Skin Cancer
Interventions
DEVICE

percutaneous, laparoscopic or laparotomy lesion electrochemotherapy

All patients will receive Bleomycin intravenously with a dosage of 15.000 IU/m2. After a drug distribution time of 8 minutes, the lesions will be electroporated using the Cliniporator (IGEA S.P.A., Carpi, Italy), applying special handpieces depending on the route used: laparoscopic electrode, flexible and expandable for the laparoscopic procedure, linear or hexagonal electrode for laparotomy surgical access, variable geometry electrode for percutaneous access. The ECT procedure must be completed within 40 minutes.

Trial Locations (1)

35128

RECRUITING

Istituto Oncologico Veneto, Padua

All Listed Sponsors
collaborator

IGEA

INDUSTRY

lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT06753136 - Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype | Biotech Hunter | Biotech Hunter